April 2018

Neon Medical Marijuana sign. Image-Laurie Avacado Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder (ASD).  The study, scheduled to launch […]

by

PHOENIX, April 27, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome, a rare genetic disease characterized […]

by

The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a role in the decision-making process. The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a […]

by

(Photo credit LUIS ROBAYO/AFP/Getty Images) (Photo credit LUIS ROBAYO/AFP/Getty Images) BOISE, Idaho (KIVI) — The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a role in the decision-making process. A panel of federal advisers unanimously voted last week to recommend […]

by

BOISE, Idaho — The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a role in the decision-making process. A panel of federal advisers unanimously voted last week to recommend the approval of the Epidiolex, the first prescription cannabidiol medicine, to […]

by

PHOENIX, April 27, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome, a rare genetic disease characterized […]

by

The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a role in the decision-making process. The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a […]

by

Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder (ASD). The study, scheduled to launch in approximately one year, is funded […]

by

Announces Meeting with FDA to Obtain Consent for Start of Phase 3 Pivotal Registration Study in Treatment of Acute GVHDAndProvides Corporate Update and Outlook for 2018 SAN FRANCISCO and TEL AVIV, Israel, April 26, 2018 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera“) today issued the following letter to shareholders […]

by

BOISE, Idaho — The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a role in the decision-making process. A panel of federal advisers unanimously voted last week to recommend the approval of the Epidiolex, the first prescription cannabidiol medicine, to […]

by